Phathom Pharmaceuticals
PHAT
83 hedge funds and large institutions have $562M invested in Phathom Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 33 increasing their positions, 14 reducing their positions, and 18 closing their positions.
2,600% more call options, than puts
Call options by funds: $27K | Put options by funds: $1K
136% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 14
9.49% more ownership
Funds ownership: 81.45% → 90.94% (+9.5%)
0% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 18
1% less funds holding
Funds holding: 84 → 83 (-1)
31% less capital invested
Capital invested by funds: $820M → $562M (-$258M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$44.6M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$7.8M |
| 3 |
6CM
683 Capital Management
New York
|
+$6.84M |
| 4 |
BlackRock
New York
|
+$6.83M |
| 5 |
AG
Artal Group
Luxembourg
|
+$4.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.09M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$6.21M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.95M |
| 4 |
WCM Investment Management
Laguna Beach,
California
|
-$3.35M |
| 5 |
PMAM
Penn Mutual Asset Management
Conshohocken,
Pennsylvania
|
-$2.79M |
PHAT Hedge Fund Activity: Q4 2021 in Review
83 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q4 2021, worth a combined $562M — down 31% from $820M a quarter earlier.
Fund positioning in PHAT was balanced in Q4 2021: 18 funds opened new positions, 18 closed out, 33 added to existing stakes and 14 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $44.6M. The largest seller was Great Point Partners, exiting entirely with an estimated $7.09M sold.
- 83 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q4 2021, down from 84 in Q3 2021.
- Funds reported $562M of Phathom Pharmaceuticals stock for Q4 2021, down 31% quarter-over-quarter.
- 18 funds opened new Phathom Pharmaceuticals positions in Q4 2021 and 18 closed out, a net change of 0 holders.
- The largest Phathom Pharmaceuticals buyer in Q4 2021 was Avidity Partners Management, an estimated $44.6M added.
- The largest Phathom Pharmaceuticals seller in Q4 2021 was Great Point Partners, an estimated $7.09M sold.
Based on aggregated 13F filings for Q4 2021.